Working… Menu

Assessment of Ventilation-perfusion Abnormalities in Patients With Stable Smoking-related Airways Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00180843
Recruitment Status : Terminated (lack of resources research fellow left)
First Posted : September 16, 2005
Last Update Posted : September 24, 2013
Information provided by (Responsible Party):
Philip Ind, Imperial College London

Brief Summary:
Subjects undergo history, examination, lung function assessment after informed consent has been obtained. All subjects will undergo ventilation-perfusion scans. If there first scan is normal they will undergo a second and final scan four weeks later. If abnormal they will undergo two further scans with either nebulized bronchodilator or nebulized saline prior to their second and third scans. Each time they will have repeat lung function tests prior to scanning. We will examine the regional changes in ventilation and perfusion and there relationship to lung function.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease Drug: salbutamol + ipratropium bromide nebules Drug: nebulized saline Not Applicable

Detailed Description:
As in Brief description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Assessment of Ventilation-perfusion Abnormalities in Patients With Smoking-related Airways Disease in Stable Condition and the Effect of Bronchodilator Therapy
Study Start Date : September 2005
Actual Primary Completion Date : February 2008
Actual Study Completion Date : February 2008

Arm Intervention/treatment
Placebo Comparator: saline control
nebulized saline
Drug: nebulized saline
Active Comparator: salbutamol and ipratropium bromide nebules
salbutamol 2.5 mg and ipratropium bromide 0.5 mg
Drug: salbutamol + ipratropium bromide nebules
Other Names:
  • albuterol
  • Ventolin
  • Atrovent

Primary Outcome Measures :
  1. scan grade [ Time Frame: post scan ]
    previously validated grading score

Secondary Outcome Measures :
  1. lung function [ Time Frame: pre scan ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • FEV1 < 70% predicted at baseline on spirometry
  • significant smoking history or alpha 1 antitrypsin deficiency
  • no evidence of current infection or restrictive lung disease

Exclusion Criteria:

  • history of other significant respiratory disease
  • significant respiratory infection within 6 weeks
  • history of significant physical or mental illness rendering them unfit for the study in the opinion of the investigator
  • taken part in any other research within the past 12 months, or received exposure to ionizing radiation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00180843

Layout table for location information
United Kingdom
Imperial College Hammersmith Campus
London, United Kingdom, W12 0HS
Sponsors and Collaborators
Imperial College London
Layout table for investigator information
Principal Investigator: Philip W Ind, MB BChir MRCP Imperial College Hammersmith
Layout table for additonal information
Responsible Party: Philip Ind, Consultant Physician, Imperial College London Identifier: NCT00180843    
Other Study ID Numbers: 04/6741
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: September 24, 2013
Last Verified: September 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Lung Diseases
Respiratory Tract Diseases
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Cholinergic Antagonists
Cholinergic Agents